| Trial ID: | L6724 |
| Source ID: | NCT02456428
|
| Associated Drug: |
Dpp-4 Inhibitors
|
| Title: |
Incretin-based Drugs and the Risk of Heart Failure
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: DPP-4 inhibitors|DRUG: GLP-1 analogs|DRUG: Insulins|DRUG: Biguanides|DRUG: Sulfonylureas|DRUG: Thiazolidinediones|DRUG: Alpha-glucosidase inhibitors|DRUG: Meglitinides
|
| Outcome Measures: |
Primary: Hospitalization for incident heart failure, Patients hospitalized for incident heart failure (HF) recorded in either the discharge abstract or hospitalization record with the following ICD codes: ICD-9 code: 428.x ICD-10 code: I50.x For patients who had no history of prior HF, cases were identified by the presence of a HF diagnosis in any position (most responsible, primary, or secondary), while for patients with a history of established HF, the event definition was restricted to those with a HF diagnosis as the primary or most responsible reason for hospitalization., Patients were followed from the date of study cohort entry until hospitalization for incident heart failure, censoring, or for up to 87 months. |
|
| Sponsor/Collaborators: |
Sponsor: Canadian Network for Observational Drug Effect Studies, CNODES | Collaborators: Drug Safety and Effectiveness Network, Canada|Canadian Institutes of Health Research (CIHR)
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
1499650
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2014-03
|
| Completion Date: |
2015-05
|
| Results First Posted: |
|
| Last Update Posted: |
2016-04-19
|
| Locations: |
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, H3T1E2, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT02456428
|
